Takemura Nobuyuki, Saiura Akio, Ito Hiromichi, Ito Kyoji, Inagaki Fuyuki, Mihara Fuminori, Yagi Shusuke, Enomoto Naoki, Nohara Kyoko, Inoue Yosuke, Takahashi Yu, Yamada Kazuhiko, Kokudo Norihiro
Department of Surgery, Hepato-Biliary Pancreatic Surgery Division, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Hepatobiliary Pancreatic Surgery, Juntendo University Hospital, Tokyo, Japan.
Glob Health Med. 2022 Feb 28;4(1):57-60. doi: 10.35772/ghm.2021.01102.
Hepatectomy for gastric cancer liver metastases (GCLM) has a 5-year survival rate of 9-42%; however, indications for hepatectomy remain unclear. Many researchers have reported prognostic factors for GCLM after hepatectomy, but surgical indications vary according to the literature. Furthermore, the indication for optimal candidates for neoadjuvant chemotherapy and intensive chemotherapy is also unclear. To understand the indications for surgery and chemotherapy intended for hepatectomy for GCLM, a new treatment algorithm was created based on previously reported evidence from the viewpoint of hepatic surgeons.
胃癌肝转移（GCLM）的肝切除术5年生存率为9% - 42%；然而，肝切除术的指征仍不明确。许多研究人员报告了肝切除术后GCLM的预后因素，但根据文献，手术指征各不相同。此外，新辅助化疗和强化化疗的最佳候选者的指征也不明确。为了了解GCLM肝切除术的手术和化疗指征，从肝脏外科医生的角度出发，基于先前报道的证据创建了一种新的治疗算法。
